Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
344 Results for "
GLUT2-null hepatocytes
" in MedChemExpress (MCE) Product Catalog:
Products (344)
344 Results for "GLUT2-null hepatocytes" in MCE Product Catalog:
Cat. No.: HY-W012974R
CAS No.: 144-90-1
Synonyms: β-Aminoisobutyric acid (Standard); BAIBA (Standard)
Domaines de recherche:
3-Aminoisobutyric acid (Standard) is the analytical standard of 3-Aminoisobutyric acid. This product is used for research and analytical applications. 3-Aminoisobutyric acid (β-Aminoisobutyric acid) exhibits anti-inflammatory and antioxidant effects. It increases the expression of brown fat cell-specific genes in white adipose tissue and enhances fatty acid β-oxidation in hepatocytes. 3-Aminoisobutyric acid alleviates insulin resistance and inflammation induced by palmitic acid or a high-fat diet in mice via the AMPK–PPARδ-dependent pathway. 3-Aminoisobutyric acid is a catabolite of thymine and valine in skeletal muscle [2] .
Target:
Carboxylesterase (CES) Free Fatty Acid Receptor Reactive Oxygen Species (ROS) Mitochondrial Metabolism Ferroptosis Apoptosis
Domaines de recherche:
GR148672X is an inhibitor of carboxylesterase 1 (CES1) and hepatic microsomal triglyceride hydrolase (TGH). GR148672X blocks the catalytic activity of CES1, impairs the functions of triglyceride and cholesteryl ester lipase, reduces triglyceride mobilization and secretion, and decreases apolipoprotein B-100 secretion in primary rat hepatocytes. Under low-glucose conditions, GR148672X inhibits the survival of colorectal cancer cells by reducing free fatty acid availability, inducing toxic triglyceride accumulation, ROS production, mitochondrial damage, ferroptosis and apoptosis. GR148672X can be used in studies related to colorectal cancer and atherosclerosis [2].
Cat. No.: HY-132604
CAS No.: 2175009-08-0
Synonyms: ARO-AAT
Target:
Domaines de recherche:
Fazirsiran (ARO-AAT) is a second-generation RNAi agent. Fazirsiran consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively reduce Alpha1-antitrypsin (AAT) synthesis and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease. Alpha-1 antitrypsin deficiency (AATD) is caused by mutations in the alpha-1 antitrypsin (SERPINA1) gene.
Cat. No.: HY-19581R
CAS No.: 102280-35-3
Domaines de recherche:
Baquiloprim (Standard) is the analytical standard of Baquiloprim (HY-19581). This product is intended for research and analytical applications. Baquiloprim is an orally active Antibiotic and selective inhibitor of Bacterial Dihydrofolate reductase (DHFR), with an IC50 of 19 nM against E. coli and an IC50 of 190 μM against rat liver dihydrofolate reductase. Baquiloprim is a bacteriostatic broad-spectrum antibacterial agent that acts against Gram-negative and Gram-positive bacteria. Baquiloprim inhibits glucuronidation in cultured hepatocytes. Baquiloprim can be used in research related to Pasteurella haemolytica infection, bacterial infection, Escherichia coli diarrhea, bacterial infection in pigs, and pneumonic pasteurellosis [2] .
Cat. No.: HY-E70748
Target:
Domaines de recherche:
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET D1228H is a mutant of MET. MET D1228H Recombinant Human Active Protein Kinase is a recombinant MET D1228H protein that can be used to study MET D1228H-related functions .
Cat. No.: HY-E70749
Target:
Domaines de recherche:
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET D1228N is a mutant of MET. MET D1228N Recombinant Human Active Protein Kinase is a recombinant MET D1228N protein that can be used to study MET D1228N-related functions .
Cat. No.: HY-E70750
Target:
Domaines de recherche:
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET F1200I is a mutant of MET. MET F1200I Recombinant Human Active Protein Kinase is a recombinant MET F1200I protein that can be used to study MET F1200I-related functions .
Cat. No.: HY-E70751
Target:
Domaines de recherche:
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET G1163R is a mutant of MET. MET G1163R Recombinant Human Active Protein Kinase is a recombinant MET G1163R protein that can be used to study MET G1163R-related functions .
Cat. No.: HY-E70752
Target:
Domaines de recherche:
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET L1195V is a mutant of MET. MET L1195V Recombinant Human Active Protein Kinase is a recombinant MET L1195V protein that can be used to study MET L1195V-related functions .
Cat. No.: HY-E70753
Target:
Domaines de recherche:
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET M1250T is a mutant of MET. MET M1250T Recombinant Human Active Protein Kinase is a recombinant MET M1250T protein that can be used to study MET M1250T-related functions .
Cat. No.: HY-E70755
Target:
Domaines de recherche:
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230C is a mutant of MET. MET Y1230C Recombinant Human Active Protein Kinase is a recombinant MET Y1230C protein that can be used to study MET Y1230C-related functions .
Cat. No.: HY-E70756
Target:
Domaines de recherche:
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230D is a mutant of MET. MET Y1230D Recombinant Human Active Protein Kinase is a recombinant MET Y1230D protein that can be used to study MET Y1230D-related functions .
Cat. No.: HY-E70757
Target:
Domaines de recherche:
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230H is a mutant of MET. MET Y1230H Recombinant Human Active Protein Kinase is a recombinant MET Y1230H protein that can be used to study MET Y1230H-related functions .
Cat. No.: HY-E70758
Target:
Domaines de recherche:
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1235D is a mutant of MET. MET Y1235D Recombinant Human Active Protein Kinase is a recombinant MET Y1235D protein that can be used to study MET Y1235D-related functions .
Category:
Cat. No.: HY-P11890
CAS No.: 1154403-54-9
Domaines de recherche:
Cat. No.: HY-136783
CAS No.: 333311-00-5
G6PD-IN-2 is a Plasmodium falciparum glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 value of 0.2 μM. G6PD-IN-2 exerts weak inhibitory activity on Plasmodium falciparum glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase (PfGluPho) with an IC50 value of 22.0 μM. G6PD-IN-2 inhibits growth of Plasmodium falciparum 3D7 strain and exhibits low cytotoxicity in hepatocytes. G6PD-IN-2 can be used for the research of malaria .
Cat. No.: HY-138198A
Target:
Domaines de recherche:
YIC-C8-434 is an orally active ACAT inhibitor. YIC-C8-434 selectively blocks cholesterol esterification in intestinal epithelial cells and hepatocytes without affecting the production of triglycerides or phospholipids. YIC-C8-434 effectively reduces intracellular cholesteryl ester levels and induces an increase in lipid droplet volume, exhibiting excellent cholesterol-lowering activity and safety. YIC-C8-434 disrupts the assembly of hepatitis C virus (HCV) virions, reduces HCV RNA synthesis and viral particle release. YIC-C8-434 can be used in studies related to hepatitis C virus infection [2].
Tri-GalNAc(OAc)3 TFA is a trivalent N-acetylgalactosamine (GalNAc) derivative that can be used to synthesize GalNAc-LYTAC. Tri-GalNAc is a specific ligand targeting the asialoglycoprotein receptor (ASGPR), mediating the endocytosis and transport of cell surface proteins (such as EGFR, HER2) to lysosomes for degradation by lysosomal targeting chimeras (LYTACs). Tri-GalNAc significantly reduces the level of target proteins and inhibits downstream signaling pathways (such as EGFR-mediated Akt and MAPK signals). Tri-GalNAc(OAc)3 TFA can be used for hepatocyte targeting studies, and can degrade carcinogenic membrane proteins and inhibit tumor cell proliferation in liver cancer cell models .
Target:
Domaines de recherche:
MK 0686, a potent bradykinin B1 receptor antagonist, demonstrates autoinduction of metabolism in rhesus monkeys after oral administration. It undergoes significant biotransformation primarily via oxidation pathways, leading to the formation of metabolites like M11 and M13 in rhesus liver microsomes. This metabolic induction is mediated by CYP2C75, as evidenced by increased mRNA expression, protein levels, and catalytic activity of this enzyme in hepatocytes and liver microsomes from MK 0686-treated animals. The autoinduction phenomenon suggests that MK 0686 enhances its own metabolism by upregulating CYP2C75, potentially influencing its systemic exposure and pharmacokinetics over time .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
